BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2021

View Archived Issues

Aston Sci studies AST-021p for advanced solid tumors in phase I

Read More

DIO2 is a regulator of mitochondrial activity in developing human cardiomyocytes

Read More

TruLarv standardized Galleria mellonella developed for screening new antimicrobials

Read More

New beta-amyloid PET imaging agent [18F]Flotaza shows promise in Alzheimer's disease brain

Read More

Positive interim data from phase Ib study of ARO-HIF2 in clear cell renal cell carcinoma

Read More

First patient dosed in phase IIb study of Lomecel-B in hypoplastic left heart syndrome

Read More

Positive phase I data for UBX-1325 in patients with advanced vascular eye disease

Read More

FDA clears IND for AGEN-1777

Read More

Vanderbilt University patents muscarinic M4 receptor antagonists

Read More

Shionogi discloses new HDAC2 inhibitors

Read More

Kymera Therapeutics patents new PROTACs

Read More

Eli Lilly and Company synthesizes GTPase KRAS mutant inhibitors

Read More

Ifenprodil will not advance into phase III trial for COVID-19

Read More

Intra-Cellular Therapies identifies new gamma-carboline derivatives

Read More

NMPA accepts IND application for TST-002 anti-sclerostin monoclonal antibody

Read More

SYNB-8802 significantly lowers urinary oxalate in NHP model of hyperoxaluria

Read More

Dapagliflozin similarly reduces risk of worsening in Black and White patients with HFrEF

Read More

Adamtsl3 knockout leads to dilated cardiomyopathy in aortic banded mice

Read More

APOBEC3B may be a therapeutic target for treating ovarian cancer

Read More

Studies report on developmental, adult neurogenesis

Read More

NextCure's NC-762 enters phase I/II trial in advanced or metastatic solid tumors

Read More

Opiant reports topline data from confirmatory PK study of OPNT-003 for opioid overdose

Read More

FDA clears initiation of phase II trials of YH-001 and YH-003 in advanced cancers

Read More

Sorrento cleared in U.S. to begin phase II study of resiniferatoxin in knee osteoarthritis pain

Read More

EpimAb Biotherapeutics commences dosing in phase I/II trials of EMB-06 and EMB-02

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing